H.C. Wainwright analyst Yi Chen downgraded Tourmaline Bio (TRML) to Neutral from Buy with a price target of $48, down from $50, after the company entered into a merger agreement to be acquired by Novartis (NVS) for $48 per share in cash or $1.4B. The firm does not expect a competitive bid to emerge at this time.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Tourmaline Bio downgraded to Hold from Buy at Truist
- Tourmaline Bio downgraded to Neutral from Buy at Chardan
- Tourmaline Bio downgraded to Hold from Buy at Jefferies
- Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz
- Tourmaline Bio downgraded to Market Perform from Outperform at LifeSci Capital